Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905583 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL28489301 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL8980574 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL8980646 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL21916561 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL21337225 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL11256312 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL10490549 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL6501802 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 | |
| SCHEMBL1276502 | 1.00 | NPC1 (0.51) | NPC1JAK2RAB9APAX8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143405-A2 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-11-26 | — | — | WO | claimed |
| US-20060292326-A1 | Optical data store comprising a cobalt phthalocyanine with an axial substituent and axial ligand in an information photoinscribtible layer | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1563014-A1 | OPTICAL DATA MEMORIES COMPRISING COBALT PHTALOCYANIN WITH AN AXIAL SUBSTITUENT AND AXIAL LIGAND IN AN INFORMATION PHOTOINSCRIBTIBLE LAYER | LANXESS Deutschland GmbH (DE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004046253-A1 | OPTICAL DATA MEMORIES COMPRISING COBALT PHTALOCYANIN WITH AN AXIAL SUBSTITUENT AND AXIAL LIGAND IN AN INFORMATION PHOTOINSCRIBTIBLE LAYER | LANXESS DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | claimed |
| EP-1322906-A1 | OPTICAL DATA STORAGE DEVICE CONTAINING A CO-PHTHALOCYANIN COMPLEX IN THE OPTICALLY WRITABLE INFORMATION LAYER | Bayer Aktiengesellschaft (DE) | 2003-07-02 | — | — | EP | claimed |
| WO-2002025205-A1 | OPTICAL DATA STORAGE DEVICE CONTAINING A CO-PHTHALOCYANIN COMPLEX IN THE OPTICALLY WRITABLE INFORMATION LAYER | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | claimed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | claimed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-109651367-B | Method for preparing 1, 4-dihydroquinoline and pyrrolo [1,2-a ] quinoline compounds | 安徽理工大学 | 2021-01-19 | — | — | CN | disclosed |
| CN-108456588-A | A kind of vegetable insulating oil and preparation method thereof | 重庆大学 | 2018-08-28 | — | — | CN | disclosed |
| EP-0484857-B1 | Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent | SAGAMI CHEM RES (JP) | 1997-05-07 | — | — | EP | disclosed |
| US-5624680-A | SKIN ABSORPTION OF DRUGS WITH POLYETHERSILOXANE BLOCK COPOLYMERS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0710688-A1 | HYDROXYSILYL-TERMINATED POLYOXYETHYLENE COMPOUND, QUATERNARY-SALT-TERMINATED BLOCK COPOLYMER, AND PERCUTANEOUS ABSORPTION PROMOTER | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5200488-A | POLYORGANOSILOXANE HAVING A QUATERNARY SALT AT ITS ONE TERMINAL AND PERCUTANEOUS ABSORPTION-PROMOTING AGENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0484857-A2 | Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-4352696-A | Process and composition | THE UPJOHN COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
| US-4257995-A | STORAGE STABILITY | THE UPJOHN COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | NPC1 760/4885JAK2 1407/4885RAB9A 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.